[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-with-mildly-reduced-ejection-fraction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-with-mildly-reduced-ejection-fraction":207},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,70,107,138,161,182],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100595823",false,"NCT07037459","Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)","MARITIME-HF","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of informed consent.\n* BMI ≥ 30.0 kg\u002Fm\\^2 at randomization.\n* HF diagnosed for at least 30 days with New York Heart Association (NYHA) Class II-IV at the time of informed consent.\n* Managed with HF standard of care therapies.\n* Left ventricular ejection fraction (LVEF) of \\> 40% within 12 months before randomization.\n\nExclusion Criteria:\n\n* History of any of the following within 60 days prior to or during screening: Type I (spontaneous) MI, valvular replacement or repair, coronary revascularization, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke.\n* HF due to: hypertrophic cardiomyopathy, infiltrative cardiomyopathy, active or chronic myocarditis, constrictive pericarditis, cardiac tamponade, arrhythmogenic right ventricular or left ventricular cardiomyopathy\u002Fdysplasia, uncorrected primary valvular heart disease, clinically significant congenital heart disease.\n* Hospitalized with acute decompensated HF at the time of or during the screening period.\n* Type 1 diabetes mellitus, or any type of diabetes with the exception of T2DM or history of gestational diabetes.\n* For participants with a prior diagnosis of T2DM (including those diagnosed during screening):\n\n  1. HbA1c \\> 10.0% (86 mmol\u002Fmol) at screening\n  2. Uncontrolled diabetes requiring immediate therapy\n  3. History of diabetic ketoacidosis or hyperosmolar state\u002Fcoma within 12 months before randomization\n  4. One or more episodes of severe hypoglycemia within 6 months before randomization and\u002For history of hypoglycemia unawareness\n  5. History or presence of either proliferative diabetic retinopathy, or diabetic maculopathy, or severe non-proliferative diabetic retinopathy; or currently receiving or planning to receive treatment for diabetic retinopathy and\u002For macular edema.\n* SBP ≥ 180 mmHg during the screening period, or on three or more blood pressure-lowering drugs with a SBP \\> 160 mmHg during the screening period (including day 1 prior to randomization).\n* History of chronic pancreatitis or acute pancreatitis in the 180 days before screening or during the screening period.\n* Any personal lifetime history of, or family history(first-degree relative\\[s\\]) of medullary thyroid carcinoma or MEN-2.\n* eGFR \\\u003C 20 mL\u002Fmin\u002F1.73 m\\^2 (CKD-EPI creatinine (Cr)-cystatin C equation) or receiving dialysis at screening.\n* Calcitonin ≥ 50 ng\u002FL (pg\u002FmL) at screening.\n* Acute or chronic hepatitis.\n* Any of the following psychiatric history:\n\n  1. History of unstable major depressive disorder or other severe psychiatric disorder within 2 years prior to screening or during the screening period\n  2. Lifetime history of suicide attempt\n  3. History of non-suicidal self-injury within 5 years prior to screening or during the screening period.\n* History of any other condition that, in the opinion of the investigator, may preclude the participant from following the protocol and completing the trial.\n* Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) agonists or antagonists, or amylin analogs within 90 days prior to or during the screening period or planned use during the conduct of the trial.","ALL","18 Years","99 Years",{"count":20,"type":21},5056,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.",[27,28,29],"Heart Failure With Preserved Ejection Fraction","Heart Failure With Mildly Reduced Ejection Fraction","Obesity",[31,29,32,33,34],"Heart Failure","Maridebart Cafraglutide","AMG 133","MariTide","RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":39},"2025-06-25",{"date":43,"type":21},"2030-09-29",{"name":45,"class":46},"Amgen","INDUSTRY",628,{"id":49,"slug":4,"hasResults":10,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100632139","NCT07509801","A Study to Evaluate the Safety and Efficacy of NT-88","A Randomized, Single-center, Blinded Analysis Clinical Study to Evaluate the Safety and Efficacy of NT-88 in Patients With Heart Failure With Chronic Mildly Reduced Ejection Fraction","Inclusion Criteria:\n\n1. Aged ≥18 years, no gender restriction;\n2. Willing to participate in the study, understand and sign the informed consent form (ICF);\n3. Established diagnosis of heart failure with signs and\u002For symptoms of heart failure; Symptoms: Dyspnea, reduced exercise tolerance, fatigue, exhaustion, etc.;Signs: Scattered moist rales in limited lung fields (clinically defined as: sparse, discontinuous, fine bubbling sounds heard in 1-2 localized lung areas during mid-to-late inspiration) or accompanied by mild cardiac murmur; Diagnostic examinations (key for confirmation): Echocardiography, natriuretic peptide testing, electrocardiography.\n4. Cardiac imaging examination (primarily echocardiography) demonstrating LVEF 41%-49%;\n5. New York Heart Association (NYHA) functional Class II-III (see Appendix 1);\n6. Clinically stable condition with no significant changes in symptoms, signs, or treatment regimen for at least 3 months;\n7. Normal cognitive function.\n\nExclusion Criteria:\n\n1. Known allergy to any component of the investigational product;\n2. Complicated with cardiogenic shock, acute severe myocarditis, poorly controlled malignantarrhythmia, hypertrophic obstructive cardiomyopathy, constrictive pericarditis, cardiac tamponade, severevalvular disease requiring surgical intervention, or pulmonary embolism, among others;\n3. Hospitalization for acute heart failure decompensation within the past 3 months;\n4. Implantation of implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy(CRT) within 3 months;\n5. Uncontrolled hypertension, defined as resting systolic blood pressure ≥180 mmHg and\u002For diastolicblood pressure ≥110 mmHg at two separate assessments prior to randomization;\n6. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST), or total bilirubin \\>3 times theupper limit of normal (ULN) due to non-cardiac causes; estimated glomerular filtration rate (eGFR) \\\u003C15mL\u002Fmin\u002F1.73 m²; or serum potassium \\>5.5 mmol\u002FL;\n7. Acute coronary syndrome, stroke, or transient ischemic attack within 3 months; cardiac, carotid, orother major vascular surgery; percutaneous coronary intervention (PCI), carotid angioplasty, coronary arterybypass grafting (CABG), or other cardiac surgery within 3 months; or recent onset of non-cardiac conditions affecting exercise capacity, or conditions that may be exacerbated by vigorous exercise (such as infection,hepatic or renal failure, thyrotoxicosis, etc.);\n8. Major surgery within 6 months;\n9. Serious primary diseases of the liver, kidney, hematopoietic system, nervous system, endocrinesystem, or other severe systemic diseases; malignancy; or psychiatric disorders;\n10. Acute infection;\n11. Positive for human immunodeficiency virus (HIV) antibody, positive syphilis test, or hepatitis B orhepatitis C infection;\n12. Life expectancy \\\u003C1 year;\n13. Known hypersensitivity to any study drug, or history of chronic urinary tract infection, or prior orplanned bariatric surgery;\n14. Women who are pregnant, breastfeeding, or planning pregnancy;\n15. Participation in another clinical study within 3 months;\n16. Subjects deemed unsuitable for participation in this trial by the investigator.",{"count":55,"type":21},60,[57],"NA","A study to evaluate the safety and preliminary efficacy of Zuozhu Daxi in patients with chronic heart failure with mildly reduced ejection fraction",[28],"NOT_YET_RECRUITING","2026-03-29",{"date":63,"type":39},"2026-04-03",{"date":65,"type":21},"2026-03-30",{"date":67,"type":21},"2027-06-30",{"name":69,"class":46},"Guangzhou Manjing biomedicine technology co., ltd",{"id":71,"slug":4,"hasResults":10,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":10,"sex":76,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100615662","NCT07295522","Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?","PopS-HF","Inclusion Criteria:\n\n1. Female patients \\>18 \\\u003C85 years.\n2. Hospital admission within the 72 hours prior to Screening for acute heart failure with dyspnea at rest and pulmonary congestion on chest X-ray, and other signs and\u002For symptoms of heart failure such as edema and\u002For positive rales on auscultation.\n3. All measures within 24 hours prior to Randomization of systolic blood pressure ≥ 100 mmHg, and of heart rate ≥ 60 bpm.\n4. All measures within 24 hours prior to Randomization of serum potassium ≤ 5.0 mEq\u002FL (mmol\u002FL).\n5. Biomarker criteria for persistent congestion:\n\n   5.1. At Screening, NT-proBNP \\>1,800 pg\u002FmL (2,350 pg\u002FmL in case of atrial fibrillation) 5.2. At the time of Randomization (1-2 days prior to discharge), NT-proBNP \\>1,000 pg\u002FmL (1,300 pg\u002FmL in case of Atrial Fibrillation) to ensure the persistence of congestion and the acuity of the index episode).\n6. At 1 week prior to admission, at Screening, and at Visit 2 6.1. If EF\\\u003C50% (ie HFrEF or HFmrEF) either \\\u003C½ the optimal dose of ACEi\u002FARB\u002FARNi and MRA and BB or no SGLT2i (see Table) must have been prescribed 6.2. If EF\\>50% (ie HFpEF): \\\u003C½ the optimal dose of MRA (see Table) or no SGLT2i.\n7. Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Male patients\n2. Age \\\u003C 18 or \\> 85 years.\n3. Mechanical ventilation (not including CPAP\u002FBIPAP) in the 24 hours prior to Screening.\n4. Significant pulmonary disease contributing substantially to the patients' dyspnoea such as FEV1 \\\u003C1 liter or need for chronic systemic or nonsystemic steroid therapy, or any kind of primary right heart failure such as primary pulmonary hypertension or recurrent pulmonary embolism.\n5. Myocardial infarction, unstable angina or cardiac surgery within 3 months, or cardiac resynchronization therapy (CRT) device implantation within 3 months, or percutaneous transluminal coronary intervention (PTCI), within 1 month prior to Screening or during the index event.\n6. Index Event (admission for Acute Heart Failure) triggered primarily by a correctable aetiology such as significant arrhythmia (e.g., sustained ventricular tachycardia, or atrial fibrillation\u002Fflutter with sustained ventricular response \\>130 beats per minute, or bradycardia with sustained ventricular arrhythmia \\\u003C45 beats per minute), infection, severe anaemia, acute coronary syndrome, pulmonary embolism, exacerbation of Chronic Obstructive Pulmonary Disease (COPD), planned admission for device implantation or severe non-adherence leading to very significant fluid accumulation prior to admission and brisk diuresis after admission. Troponin elevations without other evidence of an acute coronary syndrome are not an exclusion.\n7. Uncorrected thyroid disease, active myocarditis, or known amyloid or hypertrophic obstructive cardiomyopathy.\n8. History of heart transplant or on a transplant list or using or planned to be implanted with a ventricular assist device.\n9. Sustained ventricular arrhythmia with syncopal episodes within the 3 months prior to screening that is untreated.\n10. Presence at Screening of any hemodynamically significant valvular stenosis or regurgitation, except mitral or tricuspid regurgitation secondary to left ventricular dilatation, or the presence of any hemodynamically significant obstructive lesion\n11. Active infection at any time during the AHF hospitalization prior to Randomization based on abnormal temperature and elevated WBC or need for intravenous antibiotics.\n12. Stroke or Transient Ischemic Attack (TIA) within the 3 months prior to Screening.\n13. Primary liver disease considered to be life threatening.\n14. Renal disease or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2 (as estimated by the simplified MDRD formula) at Screening or history of dialysis.\n15. Psychiatric or neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \\\u003C 6 months.\n16. Prior (defined as less than 30 days from screening) or current enrollment in a CHF trial or participation in an investigational drug or device study within the 30 days prior to screening or 5 half-lives of the study drug, whichever is longer.\n17. Discharge for the AHF hospitalization anticipated to be \\>14 days from admission, or to a long-term care facility. Randomization must occur within 12 days following admission and at 1-2 days prior to anticipated discharge.\n18. Inability to comply with all study requirements, due to major co-morbidities, social or financial issues or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and\u002For comply with the protocol instructions or follow-up procedures.\n19. Pregnant or nursing (lactating) women.\n20. Hypersensitivity to the active substance or to any of the excipients as indicated in Summary of Product Characteristics of Investigational Medicinal Product (IMPs).\n21. Angioedema.\n22. Severe heart failure (NYHA class IV).","FEMALE","85 Years",{"count":79,"type":21},368,[81],"PHASE4","The goal of this clinical trial is to learn whether a rapid and intensive optimization of heart failure medications in women can improve outcomes after hospitalization for heart failure. It will also investigate the safety and the tolerance of these treatments when given at full guideline-recommended doses.\n\nThe main questions it aims to answer are:\n\n1. Does intensive medication optimization reduce death or hospital readmissions for heart failure within one year?\n2. Do women benefit as much as men from intensive and full-dose heart failure therapy?\n3. Is this treatment protocol safe and feasible also in women?\n\nResearchers will compare two groups of women hospitalized for heart failure:\n\n* High-intensity care: starting and increasing all recommended heart-failure medications as quickly as possible and monitoring patients closely during the first weeks after discharge.\n* Usual care: medications are started and adjusted gradually, according to the judgment of the treating cardiologist and the patient's usual care team.\n\nThe study will follow participants for 12 months to see whether the high-intensity strategy reduces death, hospital readmission for heart failure, or worsening symptoms. It will also evaluate side effects, medication tolerance, and quality of life.\n\nParticipants will be randomly assigned to one of the two groups, attend regular follow-up visits for one year, complete a short quality-of-life questionnaire (EQ-5D).\n\nThis study will include about 360 women from 13 hospitals in Italy. It is sponsored by IRCCS Policlinico San Donato and funded by the Italian Medicines Agency (AIFA).",[31,84,85,86,28],"Acute Heart Failure","Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Failure With Preserved Ejection Fraction (HFPEF)",[88,89,90,91,92,93,94,95,96],"heart failure","women","GDMT","Pharmacological Optimization","phase IV","High intensity up-titration","Secondary prevention","Sex differences","Real world data","2026-03-25",{"date":65,"type":39},{"date":100,"type":21},"2026-04-08",{"date":102,"type":21},"2028-06-08",{"name":104,"class":105},"IRCCS Policlinico S. Donato","OTHER",13,{"id":108,"slug":4,"hasResults":10,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":10,"sex":16,"minAge":114,"maxAge":77,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100489346","NCT05651919","PBMC as Biomarkers of Diabetic Cardiomyopathy","Use of Peripheral Blood Mononuclear Cells as biOmarkers of diaBetic cardIomyopathy","MOBI","Inclusion Criteria:\n\nInclusion criteria common to the 4 groups:\n\n* Patient attending a scheduled cardiology or endocrinology follow-up visit\n* Patient fasting for blood sampling\n* Male or female aged 40 to 85 years inclusive\n* Patient not opposing participation in this research\n* Patient agreeing to the storage of biological samples and to genetic analyses\n\nGroup 1: No-T2D +MS \u002F No-HF (control group)\n\n\\- Patient without T2D or MS and without heart failure coming to a consultation or day hospital for another reason (e.g. screening for atypical symptom, etc.)\n\nGroup 2: No-T2D +MS \u002F HFpEF or HFmrEF\n\n* Patient without T2D or MS\n* HFpEF or HFmrEF. diagnosed\n\nGroup 3: T2D+MS \u002F no-HF\n\n* Patient diagnosed with T2D+MS\n* \\- Absence of HF\n\nGroup 4: T2D +MS \u002F HFpEF or HFmrEF\n\n* Patient diagnosed with T2D and MS\n* HFpEF or HFmrEF. diagnosed\n\nExclusion Criteria:\n\nNon-inclusion criteria common to the 4 groups:\n\n* History of cardiovascular disease (valvular disease \\[greater than moderate severity\\], radiation-induced, post-cardiotoxic chemotherapy, amyloidosis, etc.) other than HFpEF or HFmrEF\n* Acute or ongoing systemic inflammatory or infectious disease\n* History of known coronary artery disease\n* Uncontrolled hypertension (\\>160\u002F100 mmHg)\n* Pregnant or breastfeeding women (based on interview)\n* Persons deprived of liberty by judicial or administrative decision\n* Persons undergoing psychiatric care\n* Patient under legal protection (guardianship or curatorship)\n* Subject participating in another interventional study with an ongoing exclusion period\n* Chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n\nGroup 1: No-T2D +MS \u002F No-HF (control group)\n\n* Presence of diabetes (whatever the type) and MS\n* Presence of heart failure or other known heart disease\n\nGroup 2: No-T2D +MS \u002F HFpEF or HFmrEF\n\n* Presence of diabetes (whatever the type) and MS\n* Left Ventricular Ejection Fraction (LVEF) on ultrasound ≤ 40%\n\nGroup 3: T2D+MS \u002F no-HF\n\n* Without diabetes or other type of diabetes than T2D\n* Presence of Heart failure (all types)\n\nGroup 4: T2D +MS \u002F HFpEF or HFmrEF\n\n* Absence of diabetes or presence of another type of diabetes than T2D\n* LVEF on ultrasound ≤ 40%","40 Years",{"count":116,"type":21},175,"OBSERVATIONAL","Type 2 diabetes (T2D), especially when associated with metabolic syndrome (MS) is at high risk to develop heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF), and the specific impact of T2D+MS in cardiac function impairment is usually known as \"diabetic cardiomyopathy\" (DC). Cardiac remodelling (ie hypertrophy) and subtle myocardial dysfunction are highly prevalent in T2D+MS but not specific enough to predict further HFpEF or HFmrEF. Also, current biomarkers can identify but do not predict HFpEF or HFmrEF in T2D patients; Furthermore, specific biomarkers are needed. Peripheral blood mononuclear cells (PBMC) obtained from a peripheral blood sample can provide insights from calcic and inflammatory pathways, and may identify more specific molecular signatures shared between T2D+MS and HFpEF.",[120,121,27,28],"Type 2 Diabetes","Metabolic Syndrome",[123,124,125,126,127],"Type 2 diabetes","metabolic syndrome","Heart Failure with Preserved Ejection Fraction","heart failure with mildly reduced ejection fraction","PBMC","2026-03-23",{"date":130,"type":39},"2026-03-27",{"date":132,"type":39},"2023-05-23",{"date":134,"type":21},"2028-05-23",{"name":136,"class":105},"Hospices Civils de Lyon",1,{"id":139,"slug":4,"hasResults":10,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":137},"100613923","NCT07272902","Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication","A Randomized Ablation-based Atrial Fibrillation Rhythm Control Versus Rate Control Trial in Patients With Heart Failure and Preserved Ejection Fraction (CABANA-RAFT HF): A Pilot Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of atrial fibrillation (documented on Holter, rhythm strip, or ECG)\n* New York Heart Association (NYHA) class II-III heart failure\n* Left ventricular ejection fraction (LVEF) \\>40%\n* Meet specific NT-proBNP criteria:\n* If HF hospitalization within 6 months prior to screening: NT-proBNP \\>200 pg\u002Fml (if not in AF at screening) or \\>600 pg\u002Fml (if in AF at screening)\n* Otherwise: NT-proBNP \\>300 pg\u002Fml (if not in AF at screening) or \\>900 pg\u002Fml (if in AF at screening)\n* On stable guideline-directed medical therapy for ≥1 month\n* On stable diuretic dose for ≥2 weeks\n* Suitable for either ablation-based rhythm control or rate control strategy\n\nExclusion Criteria:\n\n* Permanent atrial fibrillation diagnosis\n* Prior catheter ablation for atrial fibrillation\n* NYHA class IV heart failure\n* Rheumatic heart disease\n* Moderate or severe mitral stenosis\n* Mechanical mitral valve\n* Severe aortic stenosis or severe aortic\u002Fmitral regurgitation\n* Renal failure requiring dialysis\n* Contraindication to oral anticoagulation\n* Infiltrative cardiomyopathies\n* Complex congenital heart disease\n* Untreated thyroid disease\n* Acute coronary syndrome or coronary artery bypass surgery within 12 weeks\n* Participation in another clinical trial\n* Inability to provide informed consent\n* Other serious non-cardiovascular condition with life expectancy ≤1 year\n* Age \\\u003C18 years",{"count":145,"type":21},84,[57],"This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase will determine if a larger study can be successfully carried out to see which approach better improves survival, reduces hospitalizations, and enhances quality of life.",[149,28,86,150,151],"Atrial Fibrillation (AF)","Rate Control","Rhythm Control","2026-02-12",{"date":154,"type":39},"2026-02-17",{"date":156,"type":39},"2026-01-01",{"date":158,"type":21},"2027-10",{"name":160,"class":105},"Nova Scotia Health Authority",{"id":162,"slug":4,"hasResults":10,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":137},"100582407","NCT06862908","A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Subjects With HFpEF（Heart Failure With Preserved ejectIon Fraction）or HFmrEF（Heart Failure With Mildly Reduced Ejection Fraction）Combined With Obesity","Inclusion criteria:\n\n1. Age ≥18 at the time of signing the informed consent.\n2. BMI≥28kg\u002Fm2.\n3. NYHA class II-III.\n4. There were no hospitalizations due to heart failure at screening visit (V1) to randomized visit (V2).\n5. KCCQ-CSS score \\\u003C 80 during the screening period and before randomization.\n6. Medication for chronic diseases: If used before screening, the dose should be stable for ≥4 weeks; If not used before screening, the drug should also be stopped for ≥4 weeks.\n7. The women of childbearing potential（WOCBP） agrees to use the contraceptive method prescribed in this protocol for the entire study period and for 3 months after the final treatment. Pregnancy test results for fertile women during the screening period must be negative. Female subjects should not breastfeed.\n8. Voluntarily sign the informed consent form, and be willing to strictly abide by the requirements and restrictions of the informed consent form and the protocol throughout the study period, including but not limited to: maintaining a stable diet and exercise lifestyle, injecting the study drugs as planned, and keeping a study diary.\n\nExclusion criteria:\n\n1. myocardial infarction, stroke, or transient ischemic attacks, hospitalization for acute heart failure requiring any ventilatory and circulatory support devices (such as IABP ,I MPELLA, ECMO, CRRT, etc.) within 3 months before screening.\n2. Unstable angina pectoris or HF decompensation requiring IV diuretics, IV inotropes, or IV vasodilators within 30 days before screening.\n3. Poorly controlled hypertension at the screening stage, with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg. Or systolic blood pressure \\\u003C 90mmHg during screening.\n4. Had previously undergone or planned to undergo bariatric surgery during the study period.\n5. The presence of endocrine diseases or medical history that may significantly affect body weight.\n6. Previous diagnosis of type 1 diabetes or specific type diabetes.\n7. Use of GLP-1R agonists or glucagon receptor (GLP-1R\u002FGCGR) agonists or GIPR (Glucagon dependent insulinotropic polypeptide) within 3 months before screening receptor) \u002FGLP-1R agonist or GIPR\u002FGLP-1R\u002FGCGR agonist; Participants who stopped using these drugs more than 3 months prior to screening due to lack of efficacy or intolerance should also be excluded.\n8. Use of insulin in the 3 months prior to screening to control diabetes, except for short-term (cumulative ≤14 days) use of insulin in acute conditions, such as acute illness, hospitalization, or elective surgery. The last insulin treatment was less than 14 days from the screening date.\n9. History of medullary thyroid carcinoma, multiple endocrine neoplasia (MEN) 2A or 2B or family history.\n10. Clinically significant gastric empting abnormalities (such as severe diabetic gastroparesis, gastric pyloric obstruction, etc.) or gastrointestinal surgery.\n11. Active or untreated malignancies were present within 5 years prior to screening, or clinical malignancies were in remission (except in subjects with no recurrence after surgery for basal cell and squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the prostate, or papillary thyroid carcinoma).\n12. A history of atopic reactions (clinical manifestations of severe or multiple allergies) or a history of clinically significant multiple or severe drug allergies, or intolerance to local glucocorticoids, Or severe post-treatment hypersensitivity reactions (including but not limited to erythema multiforme, linear immunoglobulin A dermatitis, toxic epidermal necrolysis, anaphylaxis, angioedema, or exfoliative dermatitis).\n13. History of organ transplantation (except corneal transplantation, autologous skin transplantation), or preparing to receive organ transplantation.\n14. The investigators identified major surgeries that might be planned during the study period that would affect the participants' ability to walk.\n15. Past suicidal thoughts or behaviors.\n16. The investigator believes that the subjects are not suitable to participate in the study because of any other factors (including previous serious mental illness) that may affect the efficacy, safety evaluation or compliance of the study.",{"count":168,"type":21},141,[170],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in Chinese subjects with heart failure with ejection fraction retention\u002Fmild ejection fraction reduction (HFpEF\u002FHFmrEF) combined with obesity (BMI≥28kg\u002F㎡). This study will enroll about 141 NYHA Class II-III HFpEF\u002FHFmrEF subjects combined with obesity. Eligible participants will be randomly assigned to IBI362 4 mg, IBI362 6 mg, or placebo at a ratio of 1:1:1, randomized by concomitant atrial fibrillation during screening (history\u002Fscreening ECG).\n\nThe trial period includes a 2-week screening period, a 52-week double-blind treatment period, and a 4-week safety follow-up period.",[29,86,28],"2025-07-09",{"date":175,"type":39},"2025-07-11",{"date":177,"type":39},"2025-04-01",{"date":179,"type":21},"2027-02-11",{"name":181,"class":46},"Innovent Biologics (Suzhou) Co. Ltd.",{"id":183,"slug":4,"hasResults":10,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":137},"100478306","NCT05508256","CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction","CABA-HFPEF","INCLUSION CRITERIA:\n\n1. Age ≥18 years\n2. Signed written informed consent\n3. Clinical evidence of symptomatic heart failure (NYHA Class II-III)\n4. Paroxysmal or persistent atrial fibrillation (less than 24 months after first diagnosis, documented at least on one 12-lead ECG)\n5. Left ventricular ejection fraction (LVEF) 40-49%\n\n   OR\n\n   LVEF ≥ 50% with at least one of the following HFpEF echocardiography findings (any local measurement made during the screening epoch):\n\n   A. LA enlargement defined by at least 1 of the following: LA width (diameter) ≥3.8 cm or LA length ≥5.0 cm or LA area ≥20 cm2 or LA volume ≥55 ml or LA volume index ≥29 ml\u002Fm2\n\n   B. Left ventricular hypertrophy (septal thickness or posterior wall thickness ≥1.1 cm or relative wall thickness \\>0.42)\n6. Patients with at least 1 of the following:\n\nA. HF hospitalization (defined as HF listed as the major reason for hospitalization) within 6 months prior to screening visit and NT-proBNP \\>200 pg\u002Fml for patients in sinus rhythm (SR) or \\>600 pg\u002Fml for patients in AF at the time of blood sampling\n\nB. NT-proBNP \\>300 pg\u002Fml for patients in SR or \\>900 pg\u002Fml for patients in AF on screening ECG\n\nEXCLUSION CRITERIA:\n\n1. Patient is unable or unwilling to provide infomed consent\n2. Patient is not suitable for rhythm control of AF\n3. Previous left atrial CA or surgical therapy of AF\n4. Acutely decompensated HF, NYHA IV (patients can be enrolled after stabilization)\n5. Valvular heart disease needing interventional or surgical treatment within 3 months\n6. Heart surgery planned within 3 months\n7. Prior heart transplant or listed for heart transplant or cardiac assist device implantation\n8. Untreated hypothyroidism or hyperthyroidism (after successful treatment of thyroid dysfunction, patients may be enrolled)\n9. Patient has absolute contra-indication to oral anticoagulation\n10. Any disease that limits life expectancy to less than 1 year\n11. Active systemic infection (after successful treatment of infection, patients may be enrolled)\n12. Women currently pregnant or breastfeeding or women of childbearing potential without highly effective contraception (PEARL-Index \\\u003C 1%)\n13. Patient is included in another clinical trial\n14. Inability to comply with the study procedures",{"count":189,"type":21},1548,[81],"The objective of CABA-HFPEF is to test whether catheter ablation (CA) for atrial fibrillation (AF) can prevent adverse cardiovascular outcomes in patients with heart failure with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF).",[193,27,28],"Atrial Fibrillation",[195,88,196,197],"atrial fibrillation","catheter ablation","medial therapy","2023-03-03",{"date":200,"type":39},"2023-03-06",{"date":202,"type":21},"2023-03",{"date":204,"type":21},"2027-07",{"name":206,"class":105},"Charite University, Berlin, Germany",""]